Vantage Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Vantage Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-100	Closed	-$9K	–	831
2018 Q1	$9K	Hold	100	–	–	﹤0.01%	587
2017 Q4	$8K	Hold	100	–	–	﹤0.01%	622
2017 Q3	$9K	Hold	100	–	–	﹤0.01%	589
2017 Q2	$8K	Hold	100	–	–	﹤0.01%	593
2017 Q1	$7K	Hold	100	–	–	﹤0.01%	597
2016 Q4	$6K	Hold	100	–	–	﹤0.01%	606
2016 Q3	$7K	Hold	100	–	–	﹤0.01%	569
2016 Q2	$5K	Buy	+100	New	+$5.48K	﹤0.01%	628

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Vantage Investment Advisors's XBI Position: Q2 2018 in Review

Vantage Investment Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2018, closing a stake of 100 shares — an estimated $9K sold.

Vantage Investment Advisors first reported a position in XBI in Q2 2016 and held it in 8 quarters. The position peaked at $9K in Q1 2018. 430 funds tracked by Wall St. Rank hold XBI as of Q2 2018.

Vantage Investment Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2018 after selling out during the quarter.
Vantage Investment Advisors sold 100 State Street SPDR S&P Biotech ETF shares in Q2 2018, an estimated $9K.
Vantage Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2016 and held it in 8 quarters.
Vantage Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $9K in Q1 2018.
430 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2018.

Based on Vantage Investment Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.